Syros Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Syros Pharmaceuticals

02/03/2023 14:39

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 17 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of $1.35 per share.
    * Revenue rose 109.7% to $-754.00 thousand from a year ago;
analysts expected $3.73 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 17 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Syros Pharmaceuticals Inc shares had risen by 1.9% this
quarter.
    * The company reported a quarterly loss of $4.77 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 2
at 02:39 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.35          -0.17          Beat
 Sep. 30 2022      -4.01          -3.21          Beat
 Jun. 30 2022      -4.08          -5.40          Missed
 Mar. 31 2022      -4.70          -4.00          Beat